New White Paper: How can Belgium strengthen its position in Advanced Therapies

Belgium has built significant expertise, capabilities and assets in advanced therapies, supported by a strong scientific, clinical and industrial ecosystem. But as the global landscape evolves, the sector is also facing new realities, including financing challenges, restructuring and increasing international competition.

Developed by Deloitte, with contributions from BioWin and key opinion leaders, this new White Paper provides an objective assessment of where the Belgian advanced therapies ecosystem stands today: its strengths, remaining gaps, existing know-how and assets, and the opportunities that could emerge from these foundations.